prohibitin-targeting peptide 1 targeted - Adipotidepeptidedose peptides Prohibitin-Targeting Peptide 1: A Novel Approach to Obesity and Beyond

AdipotidepeptideDosage Chart Prohibitin-targeting peptide 1 (Prohibitin-TP01), also known by the developmental name Adipotide, represents a significant advancement in targeted therapeutic strategies. This innovative peptide is designed to selectively target specific blood vessels that supply adipose tissue, essentially starving fat cells of their blood supply.Adipotide, formerly known as Prohibitin-TP01, is a synthetic peptide that targets a protein on the surface of blood vessels supporting white adipose tissue (fat) ... The mechanism of action involves causing these vessels to shrink, leading to a reduction in fat mass2024年12月30日—Adipotide, also referred to as FTPP orProhibitin-targeting peptide 1(Prohibitin-TP01), is a synthetic compound that may mimic specific parts .... This approach holds considerable promise for the treatment of obesity and potentially other conditions linked to excessive adipose tissue.

The scientific exploration of prohibitin as a therapeutic target has revealed its crucial role in various cellular functions, including adipocyte (fat cell) function.Adipotide (Prohibitin-TP01) / Arrowhead - Obesity Prohibitin-1 (PHB), a multifunctional protein, is expressed on the surface of adipose cells and is implicated in their normal development and maintenance. By developing a targeting peptide that specifically interacts with prohibitin, researchers have created a method to precisely deliver therapeutic agents to fat tissue.

Prohibitin-targeting peptide 1 is described as a chimeric, 25-mer peptide that leverages this prohibitin interaction. Its development has been a multi-faceted endeavor, with various research groups contributing to its understanding and application. For instance, studies have explored the use of prohibitin-binding peptide (PBP), an oligopeptide that targets prohibitin-rich adipose tissue, conjugated onto nanoparticles. Another notable sequence investigated is the CKGGRAKDC peptide, which also associates with prohibitin and has been established as a vascular marker for adipose tissue. This CKGGRAKDC (SEQ ID NO: 1) targeting peptide associates with prohibitin's role in adipose tissue targeting is a key area of research.

The therapeutic potential of Prohibitin-TP01 has been evaluated in pre-clinical models. In studies involving high-fat diet-induced obesity in mice, these peptides demonstrated a significant reduction in body weight2025年8月9日—We show that theCKGGRAKDC peptide associates with prohibitin, a multifunctional membrane protein, and establish prohibitin as a vascular marker .... This suggests a paradigm shift in how obesity might be managed, moving towards targeted ablation of adipose tissueprohibitin-TP01. The compound is designed to destroy white fat, the type of fat that accumulates around the abdomen and is often associated with metabolic health issues, particularly in men.

Beyond its anti-obesity applications, the unique targeting capabilities of Prohibitin-targeting peptide 1 have also led to its investigation in other areas.2026年1月3日—Thesepeptidesdemonstrate significant reduction of body weight in a high-fat diet-induced obesity mouse model and represent a paradigm shift in ... Early-stage clinical trials, such as a Phase I study, have explored the highest tolerable dose of PROHIBITIN-TP01 in patients with advanced prostate cancer and obesity. This highlights the dual potential of the compound, addressing both a metabolic condition and a severe disease. The drug is also referred to as Adipotide, formerly known as Prohibitin-TP01, underscoring its evolving identity in the scientific and medical community.作者：K Kajimoto·2013·被引用次数：4—This nanocarrier was modified with aprohibitin-homingpeptide(KGGRAKD) that functions as atargetingmotif via a poly(ethylene glycol)2000 (PEG2000) spacer ...

The development of Prohibitin-TP01 is not limited to the peptide itself.2025年7月14日—The result is a potent compound that induces mitochondrial uncoupling and drives significant weight loss in high-fat diet-induced obese mice, ... Researchers have also explored nanotherapy approaches, such as prohibitin-targeted nanoparticles (PTNP), modified with a peptide ligand via a long PEG-linker.Arrowhead Announces Dosing of First Patient with Anti ... These nanocarriers can enhance the targeted accumulation of therapeutic agentsVascular-targeted nanotherapy for obesity. Furthermore, advancements include the creation of mixed-chirality prohibitin peptides, such as D-(RLARLAR)2, aiming for next-generation adipose-targeting prohibitin peptides capable of curbing adipocyte proliferation and function.

The field is continuously evolving, with ongoing research into the precise mechanisms and broader applications of these targeting prohibitin peptides. The journey from initial discovery to potential clinical application involves rigorous scientific investigation, including understanding the metabolism of adipocytes and the role of prohibitin in various cellular processes. The ultimate goal is to harness the power of targeted therapies like Prohibitin-targeting peptide 1 to address significant health challenges.